13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002010850
Total reported value
$731.7M
$731.7M
28 檔
46.2%
As reported in its official Q4 2024 Form 13F filing, Decheng Capital LLC's tracked investment portfolio stood at $731.7M with 28 total positions.
During Q4 2024, Decheng Capital LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CGON, NUVB, UPB) accounted for 46.2% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 39.20% | -3.34% | +16.30% | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 14.81% | +3.31% | — | |
| 3 | UPB | Upstream Bio Inc | Stock-Other | 11.58% | -1.13% | — | |
| 4 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 4.24% | -0.75% | +30.51% | |
| 5 | ILMN | Illumina Inc | Stock-Healthcare | 2.72% | — | — | |
| 6 | RCUS | Arcus Biosciences Inc | Stock-Other | 2.58% | +0.40% | -7.01% | |
| 7 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.58% | -0.29% | EXIT | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.12% | -0.03% | +11200.00% | |
| 9 | ✓ | Moonlake Immunotherapeutics | Stock-Other | 1.99% | — | +3.00% | |
| 10 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.84% | — | +6.33% | |
| 11 | ✓ | Beyondspring Inc Shs | Stock-Other | 1.71% | -0.03% | -1.52% | |
| 12 | ✓ | Merus N V | Stock-Other | 1.71% | — | — | |
| 13 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 1.63% | -0.77% | — | |
| 14 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 1.52% | +0.41% | -24.77% | |
| 15 | ACLXGBX | Arcellx Inc | Stock-Other | 1.39% | — | +298.44% | |
| 16 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.21% | — | -44.46% | |
| 17 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.21% | +0.63% | — | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.07% | — | +41.45% | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.01% | — | +6.33% | |
| 20 | BNTX | Biontech Se-adr | Stock-Other | 0.98% | — | — | |
| 21 | AURA | Aura Biosciences Inc | Stock-Other | 0.91% | — | — | |
| 22 | EQ | Equillium Inc | Stock-Other | 0.71% | +0.60% | — | |
| 23 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.48% | — | +0.54% | |
| 24 | VERA | Vera Therapeutics Inc | Stock-Other | 0.45% | — | -28.67% | |
| 25 | ATRC | Atricure Inc | Stock-Other | 0.18% | — | — | |
| 26 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.11% | +0.06% | — | |
| 27 | GRAL | Grail Inc | Stock-Healthcare | 0.04% | — | — | |
| 28 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.03% | — | — |
According to official SEC Form 13F filings, Decheng Capital LLC reported a total U.S. public equity portfolio value of $731.7M across 28 disclosed positions in Q4 2024.
During Q4 2024, Decheng Capital LLC's top holdings by market value included CGON (39.2%)、NUVB (14.8%)、UPB (11.6%). The largest single position, CGON, represented 39.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q4 2024, Decheng Capital LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.